ASTRIA THERAPEUTICS INC (ATXS)

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ATXS Crosses Below Key Moving Average Level

Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting

Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema

ATXS Crosses Below Key Moving Average Level

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema

Astria Therapeutics to Present at Upcoming Global Angioedema Forum

Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress

ATXS Makes Notable Cross Below Critical Moving Average

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics to Present at Upcoming Bradykinin Symposium

Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference

ATXS Stock Earnings: Astria Therapeutics Misses EPS for Q2 2024

ATXS stock results show that Astria Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

ATXS Stock Earnings: Astria Therapeutics Misses EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Astria Therapeutics (NASDAQ:ATXS) just reported results for the second quarter ...

Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Astria Therapeutics Chooses Ypsomed’s YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema

Astria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare Conference

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ATXS Crosses Above Key Moving Average Level

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Commit To Buy Astria Therapeutics At $7.50, Earn 25.8% Annualized Using Options

ATXS Stock Earnings: Astria Therapeutics Misses EPS for Q1 2024

ATXS stock results show that Astria Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.

ATXS Stock Earnings: Astria Therapeutics Misses EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Astria Therapeutics (NASDAQ:ATXS) just reported results for the first quarter o...

Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ATXS Makes Notable Cross Below Critical Moving Average

Oversold Conditions For Astria Therapeutics (ATXS)

Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Investors Land ATXS Even Lower Than Its Secondary Stock Offering

Notable Monday Option Activity: ATXS, UWMC, SMTC

Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE